Primrose Bio has entered a strategic partnership with ExPLoRNA Therapeutics aimed at advancing the development and marketing of mRNA medicines.
Primrose Bio brings to the partnership its expertise in engineering high-performance RNA polymerases (Prima RNApols), which enhance the yield of mRNA synthesis.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This technology not only reduces the presence of double-stranded RNA (dsRNA) but also lowers production costs, meeting the stringent manufacturing demands for various mRNA applications.
ExPLoRNA Therapeutics specialises in mRNA innovations, focusing on new cap analogues that are crucial for successful protein production.
Its technology boosts protein production, minimises dsRNA formation and reduces in vitro transcription (IVT) costs, offering notable improvements in therapeutic effectiveness.
Primrose Bio CEO Helge Zieler stated: “We are excited to work with ExPLoRNA to bring industry-leading mRNA cap analogs to the market and pairing them with Primrose Bio’s RNA polymerases.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“This partnership will result in broader manufacturing and design options for companies developing mRNA therapeutics and vaccines, facilitating access to the most efficient capping chemistry available.”
The collaboration between Primrose Bio and ExPLoRNA will lead to the joint development and offering of RNA polymerases and capping compounds that are co-optimised to improve mRNA quality, manufacturing efficiency and the safety and efficacy of therapies.
It intends to offer manufacturing solutions and new design options through advanced capping chemistry to mRNA drug developers.
ExPLoRNA Therapeutics CEO Jacek Jemielity said: “Through joining forces, we’ll advance the mRNA as a modality from the first applications to the next generation.
“We aim at creating the best synergies between our cap analogs and novel polymerases to surpass current manufacturing process and what is achievable with mRNA today.”
In March 2024, Primrose Bio and contract development and manufacturing organisation Intravacc announced a strategic collaboration to enhance conjugate vaccine development and supply.
mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
